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Aims The ESC EORP EHRA Atrial Fibrillation (AF) Ablation Long-Term registry was designed to assess management and
outcomes of AF catheter ablation procedures in Europe. To investigate the current ablation approaches and their




Data from index ablations were collected in 27 European countries at 104 centres in a prospective fashion. Pre-procedural,
procedural, and 1-year follow-up data were captured on a web-based electronic case record form. Data on the ablation
procedure were available for 3446 patients. Of these, 2513 patients and 933 patients underwent pulmonary vein isolation
(PVI) or PVI plus (PVIplus) additional ablation, respectively. The ablation strategy was limited to PVI in 81% and 56% of
patients in the PAF and non-PAF group, respectively (P< 0.001). In the non-PAF group, left atrial linear ablation and ablation
of complex fragmented atrial electrograms were more commonly performed. Arrhythmias recurrence after PVI was 29%
and 39% in the PAF and non-PAF group, respectively (P< 0.001) and 42% after PVIplus in both groups. Atrial fibrillation re-
lated hospital admissions were more common in the PVIplus group (20% vs. 14%). A very low procedural complication
rate was observed. No relevant differences were observed with regard to repeat ablation (PVI 9% and PVIplus 11%).
...................................................................................................................................................................................................
Conclusion In patients with PAF and non-PAF, the ablation strategies of PVI and PVIplus led to similar arrhythmia-free survival
rates after 1 year. A considerable hospital readmission rate was noted.
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Introduction
Catheter ablation has become an important treatment modality
for patients with symptomatic drug-refractory paroxysmal and
non-paroxysmal atrial fibrillation (PAF/non-PAF).1 Pulmonary vein
isolation (PVI) remains the cornerstone of any ablation procedure ir-
respective of patient characteristics.2 Beyond PVI, various ablation
strategies have been proposed and have been implemented into clini-
cal practice although scientific evidence from randomized studies was
scarce. Amongst others, strategies include ablation of complex frac-
tionated atrial electrograms (CFAE),3 linear lesions, ablation of low-
voltage areas (i.e. substrate modification),4 as well as identification
and ablation of rotational activities and putative atrial fibrillation (AF)
trigger sites.5 Most recently, current approaches have been called
into question by the results of the STAR AF 2 trial failing to demon-
strate any benefit of complex left atrial (LA) ablation after PVI had
been achieved.6 The European Society of Cardiology (ESC) spon-
sored EURObservational Research Programme on AF Ablation
Long-Term (EORP-AFA LT) registry aimed to assess management
and outcomes of AF catheter ablation procedures in Europe.7 The
present analysis was designed to investigate current ablation




The EORP AF Long-Term Ablation registry was set-up by EORP at the
ESC to collect data on ablation procedures across Europe. Data from in-
dex ablations were collected in 27 European countries at 104 centres in a
prospective fashion.
The details of this registry had been described in detail elsewhere.7 In
brief, National Societies of Cardiology were invited to participate in the
registry by assisting in the inclusion of centres and updating the investiga-
tors and the ESC with the legal and ethical requirements. All centres per-
forming AF ablation in each country were invited, independent of the
number of annual procedures. National coordinators obtained approval
by the national and/or local Institutional Review Board, depending on reg-
ulations in each country.
Between April 2012 and April 2015, centres were asked to enroll all
consecutive patients up to a maximum of 50 patients per centre.
Data collection
Data were captured on a web-based electronic case record form. Data
collection included demographic variables, procedural, and post-proce-
dural data as well as the 12 months of follow-up status. The latter was
performed according to the centres’ standard. On-site monitoring was
performed in 23/104 hospitals.
Statistical analysis
Statistical analysis was performed using SAS statistical software version
9.4 (SAS Institute, Inc., Cary, NC, USA). Categorical variables were
expressed using counts and percentages. Frequencies were compared us-




In total, 3660 patients were enrolled into the registry. Due to missing
data (n = 30) or because ablation had not been performed (n = 37),
3593 patients (2428 PAF and 1165 non-PAF) were analysed and
3180 (89%) completed the 1-year follow-up.
Details of demographic variables are given in Table 1. Two-thirds
of the patient population were male and the mean age was 58 ± 10
years. Patients were mildly obese (mean body mass index 28 ± 5) and
presented with few comorbidities as reflected by the relatively low
median CHA2DS2-VASc score of 1 (interquartile range q1–q3: 1–2).
Patients in the non-PAF group more frequently presented with a his-
tory of hypertension and a higher number of previous electrical car-
dioversion. Pre-procedural echocardiography revealed a larger LA
diameter in the non-PAF group.
Before ablation, 90% of patients had tried at least one antiarrhyth-
mic drug (AAD). While the use of Class I AADs was more common
in the PAF population, Class III AAD drugs were more commonly
used in the non-PAF group.
Ablation strategy
Data on the ablation procedure were available for 3446 patients. Of
these, 2513 patients and 933 patients underwent PVI or PVIplus addi-
tional ablation, respectively.
Pulmonary vein isolation only ablation
The ablation strategy was limited to PVI only in 1894 (81%) of PAF
patients and in 619 (56%) of non-PAF patients (Table 2). Patients who
were assigned to PVI had a smaller LA diameter (42 ± 6 mm vs.
44 ± 7 mm) than patients undergoing additional ablation.
The most frequently used energy source for ablation was radiofre-
quency current (78% of all ablations). As expected, open or closed ir-
rigated radiofrequency current ablation was dominant (75%), but
non-irrigated ablation (1%) and duty-cycled ablation (2%) were also
used in few cases. Among balloon catheters cryoballoon ablation was
used in 21% of cases, in particular for patients with PAF (23% vs. 15%
of all non-PAF patients; P < 0.001). Other balloon technologies were
rarely used [laser balloon; n = 25 (1%) and high intensity focused ul-
trasound; n = 2 (0.1%)].
The procedural endpoint of entrance block to the pulmonary vein
(PV) was achieved in the vast majority of cases but slightly differed for
What’s new?
• The present analysis provides unique insight into contempo-
rary ablation strategies for patients with paroxymal atrial fibril-
lation (PAF) and non-PAF in Europe.
• Pulmonary vein isolation remains the predominant ablation
strategy for PAF and non-PAF.
• The incidence of serious procedure-related complications was
low.
• Adding ablation lesions to PVI did not result in improved
outcomes.
• In the first year after atrial fibrillation ablation, a considerable
number of patients were re-admitted, required repeat ablation
and were taking antiarrhythmic drug therapy.
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each PV: left superior PV (LSPV) 98%, left inferior PV 98%, right supe-
rior PV 97%, and right inferior PV 96%.
The average procedure time (catheter insertion to removal) was
162 ± 63 min without any difference between PAF and non-PAF
patients. Mean fluoroscopy duration was 25± 22 min.
One fatal event was observed in 2512 procedures (0.04%). The
event was considered procedure related because the patient took a
fatal course after developing atrio-to-oesophageal fistula. Another
two patients experienced cardiac arrest before discharge. The rate of
cardiac perforation during PVI was 1.4% (1.6% vs. 0.5% for PAF and
non-PAF; P = 0.03). No statistical significant difference was found be-
tween cryoballoon ablation (7/570; 1.2%) and radiofrequency abla-
tion (39/2828; 1.4%; P = 1.0).
Thromboembolic events were observed in nine patients (0.3%) in-
cluding three strokes and six patients with transient ischaemic attack.
Phrenic nerve palsy was reported in 14 patients (0.6%), of which 13
occurred in the PAF and 1 in the non-PAF group. In 22 patients
(0.9%), 23 vascular access complications were observed including
hemo-/pneumothorax (n = 2), arteriovenous fistula (n = 8), and pseu-
doaneurysm (n = 13).
Pulmonary vein isolation plus ablation
Pulmonary vein isolation rates ranged from 93% (LSPV) to 94% (all
other PVs) in this subgroup (Table 3). Additional ablation beyond PVI
was performed in 933 patients (27%). While in the PAF population
only 19% additional ablation lesions were performed, in the non-PAF
population 44% of patients received additional ablation. This included
linear ablation in the left atrium in 32% of patients, of which 51% re-
ceived a roof line and 26% a LA isthmus line. Bidirectional conduction
block across the lines was achieved in 80% and 82% for the roof and
the LA isthmus, respectively.
Other strategies included ablation of CFAE (33%), ablation of gan-
glionated plexi (35%), and isolation of the superior vena cava (4%).
In the non-PAF group, LA linear ablation and ablation of CFAE
were more commonly performed (roof line 27% vs. 8%; LA isthmus
line 13% vs. 4%; CFAE ablation 15% vs. 6%, ganglionated plexi abla-
tion 11% vs. 9%; P < 0.001 for all).
Mean procedure duration was 175± 72 min including a fluoros-
copy time of 25 ± 20 min.
No peri-procedural death was observed. The rate of cardiac per-
foration for PVIplus was 1.0% (1.1% vs. 0.8% for PAF and non-PAF;
P = 0.75). One patient experienced cardiac arrest before discharge. In
two patients (0.2%), a transient ischaemic attack was noted. Phrenic
nerve palsy was reported in one patient (0.1%) in the PAF group (e.g.
2.5% of all cryoballoon ablations). In 10 patients, 12 vascular access
complications were observed (1.1%) including pneumothorax
(n = 1), arterio-venous fistula (n = 8), and pseudoaneurysm (n = 3).
Follow-up
The median follow-up after the index procedure was 12 months
(q1–q3: 12–13 months). During follow-up, 9 (0.4%) and 5 (0.6%) died
in the PVI and PVIplus group, respectively (Tables 4 and 5).
....................................................................................................................................................................................................................






AF (N 5 2428)
P-value
Age (years) N 3592 1164 2428 <0.001
Mean (SD) 57.9 (10.3) 58.9 (9.9) 57.4 (10.5)
Gender Female 1146/3593 (31.9%) 300/1165 (25.8%) 846/2428 (34.8%) <0.001
Chronic heart failure 537/2418 (22.2%) 235/869 (27.0%) 302/1549 (19.5%) <0.001
NYHA class NYHA I 172/537 (32.0%) 74/235 (31.5%) 98/302 (32.5%) 0.501
NYHA II 306/537 (57.0%) 130/235 (55.3%) 176/302 (58.3%)
NYHA III 56/537 (10.4%) 29/235 (12.3%) 27/302 (8.9%)
NYHA IV 3/537 (0.6%) 2/235 (0.9%) 1/302 (0.3%)
Hypertension 1954/3579 (54.6%) 686/1162 (59.0%) 1268/2417 (52.5%) <0.001
Diabetes mellitus 347/3583 (9.7%) 128/1161 (11.0%) 219/2422 (9.0%) 0.060
Chronic kidney disease 57/3556 (1.6%) 26/1141 (2.3%) 31/2415 (1.3%) 0.027
Previous stroke 117/230 (50.9%) 42/82 (51.2%) 75/148 (50.7%) 0.937
Previous transient ischaemic attack 95/227 (41.9%) 28/82 (34.1%) 67/145 (46.2%) 0.077
Coronary artery disease 449/2380 (18.9%) 152/854 (17.8%) 297/1526 (19.5%) 0.320
CHADS2-VASC score Median (Q1–Q3) 1.0 (1.0–2.0) 2.0 (1.0–3.0) 1.0 (1.0–2.0) 0.002
Previous electrical cardioversion 1476/3512 (42.0%) 812/1146 (70.9%) 664/2366 (28.1%) <0.001
LVEF (%) Mean (SD) 59.7 (8.4) 57.2 (9.5) 60.9 (7.6) <0.001
Left atrial diameter Mean (SD) 42.6 (6.6) 44.7 (6.7) 41.5 (6.3) <0.001
Previous antiarrhythmic drug (AAD) trial 3202/3558 (90.0%) 1015/1150 (88.3%) 2187/2408 (90.8%) 0.017
AAD class
Class I (Flec/Diso/Propa/Quinidine) 2078/3185 (65.2%) 531/1005 (52.8%) 1547/2180 (71.0%) <0.001
Class III (Amiodarone/Sotalol) 2114/3188 (66.3%) 741/1009 (73.4%) 1373/2179 (63.0%) <0.001
AF, atrial fibrillation; EHRA, European Heart Rhythm Association; LVEF, left ventricular ejection fraction; NYHA, New York Heart Failure Association; SD, standard deviation.
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After PVI only, 31% of all patients experienced a documented ar-
rhythmia recurrence, including 29% and 39% of patients in the PAF
and non-PAF group, respectively (P < 0.001; Figure 1). After PVIplus,
42% of patients had a documented arrhythmia recurrence in both
groups (P = 0.7).
The majority of arrhythmia recurrences were AF (85%) and fewer
atrial tachycardias (15%).
The arrhythmia recurrence rates post-blanking were 23.8% in the
PVI group (PAF 22.6% vs. non-PAF 27.6%; P = 0.018) and 32% in the
PVIplus group (PAF 32.7% vs. non-PAF 31.3%; P = 0.675).
Arrhythmia related hospital admissions after ablation occurred in
14% and 20% in the PVI and PVIplus group, respectively (P < 0.001).
For both groups, no differences between PAF and non-PAF were
observed.
During follow-up, 178 and 91 patients underwent electrical cardio-
version in the PVI and PVIplus group, respectively. This relates to 114
and 155 cardioversions in the PAF and non-PAF group, respectively.
After PVI, 9% of patients received a repeat ablation. A single inter-
vention was carried out in 190 patients, two and three ablation pro-
cedures in 11 and 1 patient, respectively. Of these, 9 (4%) and 6 (3%)
patients underwent surgical ablation and atrioventricular (AV) node
ablation, respectively. After PVIplus 11% of patients were re-ablated
during 1, 2, or 3 procedures in 74, 8, and 2 patients. This included sur-
gical ablation and AV node ablation, in 4 (5%) and 2 (2%) patients, re-
spectively. For both ablation strategies, no relevant differences were
observed between patients with PAF and non-PAF. Notably, atypical
atrial flutter ablation was more commonly performed after an index
PVIplus procedure compared to PVI (24% vs. 9%; P < 0.0001).
Overall, the use of membrane active AAD significantly decreased
from 56% of patients at baseline to 32% of patients at 12 months of
follow-up after PVI (P < 0.001). However, 15% of patients still used a
Class I AAD (no difference between PAF and non-PAF) and 16% of
patients used Class III AAD (15% in PAF and 20% in non-PAF;
P = 0.003).
Similarly, in the PVIplus group, the proportion of patients on-AAD
decreased from 63% to 34% at 12 months of follow-up (P < 0.0001).
In detail, Class I AAD were more often used in the PAF group (18%
vs. 11%; P < 0.003), but Class III AAD were more often used in the
non-PAF group (30% vs. 21%; P = 0.007).
Thromboembolic complications occurred in 7 (0.3%) and 1 patient
(0.1%) in the PVI and PVIplus group, respectively. In 12 (0.5%) and 11
(1.4%) patients, a pacemaker was implanted.
....................................................................................................................................................................................................................
Table 2 Procedural data for PVI
Variables Modality Total (N 5 2513) Non paroxysmal
AF (N 5 619)
Paroxysmal
AF (N 5 1894)
P-value
Age (years) Mean (SD) 57.8 (10.4) 58.9 (9.7) 57.4 (10.6) 0.002
Gender Female 789/2513 (31.4%) 149/619 (24.1%) 640/1894 (33.8%) <0.001
Left atrial diameter (mm) Mean (SD) 41.8 (6.2) 43.9 (6.1) 41.1 (6.0) <0.001
LVEF (%) Mean (SD) 59.8 (8.1) 57.1 (9.2) 60.7 (7.5) <0.001
Ablation modality
Non-irrigated radiofrequency 26/2513 (1.0%) 3/619 (0.5%) 23/1894 (1.2%) 0.119
Radiofrequency with closed irrigation 100/2513 (4.0%) 32/619 (5.2%) 68/1894 (3.6%) 0.081
Radiofrequency with opened irrigation 1779/2513 (70.8%) 474/619 (76.6%) 1305/1894 (68.9%) <0.001
Duty-cycled radiofrequency energy 50/2513 (2.0%) 4/619 (0.6%) 46/1894 (2.4%) 0.006
Cryo 530/2513 (21.1%) 92/619 (14.9%) 438/1894 (23.1%) <0.001
Laser balloon (endoscopic ablation system) 25/2513 (1.0%) 9/619 (1.5%) 16/1894 (0.8%) 0.185
High intensity focused ultrasound 2/2513 (0.1%) 0/619 (0.0%) 2/1894 (0.1%) 1.000
Complications
In-hospital death (discharge) 1/2512 (0.0%) 0/618 (0.0%) 1/1894 (0.1%) 1.000
Cardiac arrest 2/2509 (0.1%) 1/618 (0.2%) 1/1891 (0.1%) 0.432
Pericardia effusion/tamponade 34/2509 (1.6%) 3/618 (0.5%) 31/1891 (1.6%) 0.031
Phrenic nerve damage 14/2510 (0.6%) 1/618 (0.2%) 13/1892 (0.7%) 0.210
Stroke 3/2511 (0.1%) 0/618 (0.0%) 3/1893 (0.2%) 1.000
TIA 6/2510 (0.2%) 1/618 (0.2%) 5/1892 (0.3%) 1.000
A-V fistula 8/2509 (0.3%) 2/617 (0.3%) 6/1892 (0.3%) 1.000
Bleeding requiring transfusion 2/2507 (0.1%) 1/617 (0.2%) 1/1890 (0.1%) 0.432
Haematoma requiring evacuation or transfusion 8/2508 (0.3%) 2/617 (0.3%) 6/1891 (0.3%) 1.000
Pseudoaneurysm 13/2507 (0.5%) 3/617 (0.5%) 10/1890 (0.5%) 1.000
Procedure duration (min) Mean (SD) 162.1 (63.0) 157.6 (58.8) 163.6 (64.3) 0.119
Fluoroscopy time (min) Mean (SD) 25.0 (21.6) 22.0 (18.8) 26.0 (22.4) <0.001
AF, atrial fibrillation; LVEF, left ventricular ejection fraction; SD, standard deviation; TIA, transient ischaemic attack.
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Discussion
The present analysis provides unique insight into contemporary abla-
tion strategies for patients with PAF and non-PAF in Europe. Data
show that PVI remains the cornerstone of any AF ablation procedure
both for PAF and non-PAF patients who have previously failed AAD
treatment. This underlines the general adherence with expert con-
sensus recommendations.
Safety of atrial fibrillation catheter
ablation
Safety is of utmost importance when treating a non-lethal arrhythmia.
The procedural serious adverse event rate in this registry was very
low including a procedure-related mortality of 0.03% regardless of
the ablation approach. This is a relevant decrease in comparison to
previously published data, reporting a mortality rate of 0.15%.8
Recently, unequivocal evidence was provided that in-hospital mortal-
ity after AF catheter ablation declined with centre’s case volume.9
This underscores the need for transparent quality reporting and sub-
sequently definition of parameters to qualify as an ablation centre.
Similarly, the rate of thromboembolic complications was low com-
pared to historic data at 0.3%. One key factor of achieving such a low
thromboembolic complication rate is to perform the ablation proce-
dure with uninterrupted anticoagulation.10 Notably, more extensive
ablation beyond PVI did not increase the risk for peri-procedural
complications.
Selecting ablation strategies
Traditionally, type of AF (PAF vs. non-PAF) was the first parameter
to decide on an individual ablation strategy (PVI vs. PVIplus).
....................................................................................................................................................................................................................
Table 3 Procedural Data for PVI1
Variables Modality Total (N 5 933) Non paroxysmal
AF (N 5 478)
Paroxysmal
AF (N 5 455)
P-value
Age (years) Mean (SD) 58.1 (9.9) 58.7 (9.9) 57.4 (9.8) 0.153
Gender Female 310/933 (33.2%) 135/478 (28.2%) 175/455 (38.5%) <0.001
Left atrial diameter (mm) Mean (SD) 44.4 (7.4) 45.8 (7.3) 43.1 (7.2) <0.001
LVEF (%) Mean (SD) 59.6 (9.1) 57.4 (10.0) 61.6 (7.7) <0.001
Ablation modality
Non-irrigated radiofrequency 17/933 (1.8%) 8/478 (1.7%) 9/455 (2.0%) 0.728
Radiofrequency with closed irrigation 26/933 (2.8%) 12/478 (2.5%) 14/455 (3.1%) 0.599
Radiofrequency with opened irrigation 868/933 (93.0%) 449/478 (93.9%) 419/455 (92.1%) 0.268
Duty-cycled radiofrequency energy 5/933 (0.5%) 2/478 (0.4%) 3/455 (0.7%) 0.679
Cryo 17/933 (1.8%) 3/478 (0.6%) 14/455 (3.1%) 0.005
High intensity focused ultrasound 6/933 (0.6%) 5/478 (1.0%) 1/455 (0.2%) 0.218
Ablation of autonomic ganglionated plexi 323/932 (34.7%) 122/477 (25.6%) 201/455 (44.2%) <0.001
Left atrial linear lesion 301/932 (32.3%) 164/477 (34.4%) 137/455 (30.1%) 0.163
Roof line 479/933 (51.3%) 296/478 (61.9%) 183/455 (40.2%) <0.001
Mitral isthmus line 239/933 (25.6%) 143/478 (29.9%) 96/455 (21.1%) 0.002
Other left atrial linear lesion 110/933 (11.8%) 74/478 (15.5%) 36/455 (7.9%) <0.001
Ablation at fractionated electrogram sites in
the left and/or right atrium
305/932 (32.7%) 166/477 (34.8%) 139/455 (30.5%) 0.167
Superior vena cava 33/933 (3.5%) 17/478 (3.6%) 16/455 (3.5%) 0.974
Complications
In-hospital death (discharge) 0 0 0 NA
Cardiac arrest 1/928 (0.1%) 1/475 (0.2%) 0/453 (0.0%) 1.000
Phrenic nerve damage 1/933 (0.1%) 0/478 (0.0%) 1/455 (0.2%) 0.488
Pericardial effusion/tamponade 9/928 (1.1%) 4/475 (0.8%) 5/453 (1.1%) 0.75
Stroke 0 0 0 NA
TIA 2/933 (0.2%) 1/478 (0.2%) 1/455 (0.2%) 1.000
A-V fistula 8/933 (0.9%) 4/478 (0.8%) 4/455 (0.9%) 1.000
Bleeding requiring transfusion 2/933 (0.2%) 1/478 (0.2%) 1/455 (0.2%) 1.000
Haematoma requiring evacuation or transfusion 3/933 (0.3%) 2/478 (0.4%) 1/455 (0.2%) 1.000
Pseudoaneurysm 3/933 (0.3%) 2/478 (0.4%) 1/455 (0.2%) 1.000
Procedure duration (min) Mean (SD) 174.7 (72.2) 182.8 (71.2) 166.4 (72.3) <0.001
Fluoroscopy time (min) Mean (SD) 24.5 (20.3) 24.3 (21.6) 24.6 (18.7) 0.115
AF, atrial fibrillation; LVEF, left ventricular ejection fraction; NA, not applicable; SD, standard deviation; TIA, transient ischaemic attack.
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The registry data suggest that many operators still follow this deci-
sion-making process. However, other factors such as larger LA size
and the presence of comorbidities such as heart failure seem to have
triggered additional LA lesion sets. Other parameters such as the
presence of low-voltage areas or centre’s standards were not sys-
tematically captured by the registry but may have had an influence on
the applied ablation strategy.
Catheter ablation of paroxymal atrial
fibrillation
Both, for patients with PAF and for patients with non-PAF PVI only
was the predominantly selected ablation strategy. While irrigated
radiofrequency current ablation remains the most adopted technol-
ogy, the cryoballoon was used in almost every fourth patient. After
the study period, the Fire and Ice trial has shown, that both technolo-
gies are equivalent in eliminating AF but the cryoballoon may be
more effective in reducing repeat ablations, electrical cardioversions
and in preventing re-hospitalizations.11,12
Surprisingly, almost every fifth PAF patient was treated with addi-
tional ablation lesions in the left atrium. To date, no compelling evi-
dence has been presented to support these strategies. Randomized
studies and a meta-analysis have reported no additional benefit of
CFAE ablation.13,14 In turn, ablation of ganglionated plexi in addition
to PVI is supported by the results of a randomized pilot study,15 but
since then, larger confirmatory studies have not been performed.
More recently, individualized ablation strategies tailored to the
patient’s LA low-voltage areas have shown to confer better out-
comes.4,16 These results need to be confirmed in on-going multi-
centre randomized studies such as DECAAF II (NCT02529319).
Catheter ablation of non-paroxymal
atrial fibrillation
Interestingly, a PVI strategy was used in the majority of non-PAF
patients although there was widespread enthusiasm for extra PV ab-
lation in patients with more advanced forms of AF at the time of en-
rolment. Nowadays, after the publication of the STAR-AF-2 study
results, the strategies of adding linear lesions or the ablation of CFAE
were abandoned by most centres.6 Despite the fact, that 56% of the
non-PAF patients were treated with a PVI approach, balloon cathe-
ters were used in only 15% of cases. Today, several studies show that
similar results may be achieved both with the cryoballoon as well as
with the laser balloon.17,18
Nonetheless, in the presence of LA low-voltage PVI strategies
were found to be associated with poorer outcomes and it might be
necessary to extend the ablation strategy to areas in the LA. Under
these circumstances 3D mapping and tip catheter ablation remain the
technology of choice.
....................................................................................................................................................................................................................
Table 4 Follow-up data for PVI
Variables Modality Total (N 5 2513) Non paroxysmal
AF (N 5 619)
Paroxysmal
AF (N 5 1894)
P-value
FU time (in months) Mean (SD) 12.8 (3.4) 12.7 (2.9) 12.8 (3.5) 0.240
Death during 12-month FU 9/2300 (0.4%) 5/560 (0.9%) 4/1740 (0.2%) 0.044
Hospitalizations due to AF, atrial flutter,
or atrial tachycardia
313/2271 (13.8%) 88/554 (15.9%) 225/1717 (13.1%) 0.099
Stroke 2/2314 (0.1%) 0/567 (0.0%) 2/1747 (0.1%) 1.000
Transient ischaemic attack 5/2314 (0.2%) 1/567 (0.2%) 4/1747 (0.2%) 1.000
Permanent pacemaker implanted 12/2301 (0.5%) 2/560 (0.4%) 10/1741 (0.6%) 0.742
Number of patients with electrical cardioversion 178 90 88
Repeat ablation procedure
Number of procedures 0 2048/2250 (91.0%) 486/548 (88.7%) 1562/1702 (91.8%) 0.110
1 190/2250 (8.4%) 59/548 (10.8%) 131/1702 (7.7%)
2 11/2250 (0.5%) 3/548 (0.5%) 8/1702 (0.5%)
3 1/2250 (0.0%) 0/548 (0.0%) 1/1702 (0.1%)
Ablation for AF 167/202 (82.7%) 51/62 (82.3%) 116/140 (82.9%) 0.917
Ablation for AT 18/202 (8.9%) 6/62 (9.7%) 12/140 (8.6%) 0.799
AVN ablation 6/202 (3.0%) 2/62 (3.2%) 4/140 (2.9%) 1.000
Arrhythmia recurrence documented 719/2296 (31.3%) 215/557 (38.6%) 504/1739 (29.0%) <0.001
AF recurrence 619/719 (86.1%) 189/215 (87.9%) 430/504 (85.3%) 0.358
AT recurrence 98/719 (13.6%) 23/215 (10.7%) 75/504 (14.9%) 0.134
Antiarrhythmic drugs at 12-month FU
Class I 338/2292 (14.7%) 78/555 (14.1%) 260/1737 (15.0%) 0.597
Class III 368/2292 (16.1%) 112/556 (20.1%) 256/1736 (14.7%) 0.003
AF, atrial fibrillation; AT, atrial tachycardia; AVN, atrioventricular node; FU, follow-up; SD, standard deviation.
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One year outcome after catheter
ablation
The real-world outcome data of this registry are sobering.
Approximately, one-third of patients suffered from at least one
symptomatic arrhythmia recurrence in the first year after ablation.
More importantly, rehospitalization, repeat ablation, and the need for
electrical cardioversion were considerable. Given today’s economic
constraints and the lack of robust data for the reduction of mortality
and stroke this may have important implications for future reim-
bursement and more importantly for society. In the future, more
data are needed on cost-effectiveness of ablation compared to medi-
cal treatment. While, for PAF patients the use of the cryoballoon
appears to outperform RFC-guided ablation in this regard,19 more re-
search is needed on the appropriate ablation strategy for non-PAF
patients.
Noteworthy, the incidence of thromboembolic complications
was low during the first year of follow-up although approximately
20% of patients did not receive proper oral anticoagulation
therapy.
Limitation
The registry was designed to collect data on contemporary strategies
for AF ablation. Despite being a prospective registry, reporting and
selection bias cannot be fully excluded. All comparisons between
groups have to be interpreted with caution because patient allocation
was not randomized and may be subject to operator’s bias. In
particular, PVIplus may have been performed more frequently in
patients with more extensive substrate who would have had an even
poorer prognosis with a PVI approach.
Due to the non-standardized arrhythmia screening success rates
may be overestimated, but the thorough follow-up on clinical end-
points provides valuable information.
Conclusion
Today, AF catheter ablation is associated with a low procedural com-
plication rate. In patients with PAF and non-PAF, the ablation strate-
gies of PVI and PVIplus led to similar arrhythmia-free survival rates
after 1 year. Rehospitalization and repeat ablation resulted in consid-
erable healthcare consumption in the first year of follow-up.
Supplementary material
Supplementary material is available at Europace online.
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Table 5 Follow-up data for PVI1
Variables Modality Total (N 5 933) Non paroxysmal
AF (N 5 478)
Paroxysmal
AF (N 5 455)
P-value
FU time (in months) Mean (SD) 13.6 (4.1) 13.5 (4.2) 13.7 (4.1) 0.494
Death at 12-month FU 5/804 (0.6%) 2/407 (0.5%) 3/397 (0.8%) 0.683
Hospitalizations due to AF, atrial flutter,
or atrial tachycardia
153/779 (19.6%) 82/394 (20.8%) 71/385 (18.4%) 0.405
Stroke 0 0 0 NA
TIA 1/810 (0.1%) 1/413 (0.2%) 0/397 (0.0%) 1.000
Permanent pacemaker implanted 11/802 (1.4%) 7/406 (1.7%) 4/396 (1.0%) 0.546
Number of patients with electrical cardioversion N 91 65 26
Repeat ablation procedure
Number of procedures 0 711/795 (89.4%) 356/402 (88.6%) 355/393 (90.3%) 0.648
1 74/795 (9.3%) 40/402 (10.0%) 34/393 (8.7%)
2 8/795 (1.0%) 4/402 (1.0%) 4/393 (1.0%)
3 2/795 (0.3%) 2/402 (0.5%) 0/393 (0.0%)
Ablation for AF 59/84 (70.2%) 32/46 (69.6%) 27/38 (71.1%) 0.882
Ablation for AT 23/84 (27.4%) 13/46 (28.3%) 10/38 (26.3%) 0.842
AVN ablation 2/84 (2.4%) 1/46 (2.2%) 1/38 (2.6%) 1.000
Arrhythmia recurrence documented 339/801 (42.3%) 175/407 (43.0%) 164/394 (41.6%) 0.694
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Class III 204/798 (25.6%) 120/404 (29.7%) 84/394 (21.3%) 0.007
AF, atrial fibrillation; AT, atrial tachycardia; AVN, atrioventricular node; FU, follow-up; NA, not applicable; SD, standard deviation; TIA, transient ischaemic attack.
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Figure 1 Outcome after AF ablation. Overview of patients with PAF and non-PAF assigned to different ablation strategies (PVI vs. PVIplus). The
bar graphs illustrate 1 year outcome for several important clinical variables such as arrhythmia recurrence, rehospitalization, repeat ablation, and
AAD use. The P-values reflect the result of v2 testing. AF, atrial fibrillation; AAD, antiarrhythmic drug; PAF, paroxymal AF; PVI, pulmonary vein isola-
tion; PVIplus, PVI plus.
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